The use of individualized tumor response testing in treatment selection: second randomization results from the LRF CLL4 trial and the predictive value of the test at trial entry

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Leukemia 2013-02, Vol.27 (2), p.507-510
Hauptverfasser:	Matutes, E, Bosanquet, A G, Wade, R, Richards, S M, Else, M, Catovsky, D
Format:	Artikel
Sprache:	eng
Schlagworte:	631/154/436 631/67/1059/99 692/699/67/1990/283/1895 Antineoplastic Agents - pharmacology Assaying Biological Assay Cancer Research Cancer therapies Care and treatment Chronic lymphocytic leukemia Critical Care Medicine Diagnosis Drug Monitoring Drug Resistance, Neoplasm Fludarabine Follow-Up Studies Health aspects Hematology Humans Intensive Internal Medicine Letter to the Editor Letters to the editor Leukemia Leukemia, Lymphocytic, Chronic, B-Cell - blood Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy Leukemia, Lymphocytic, Chronic, B-Cell - mortality Medical prognosis Medicine Medicine & Public Health Multicenter Studies as Topic Neoplasm Recurrence, Local - blood Neoplasm Recurrence, Local - drug therapy Neoplasm Recurrence, Local - mortality Oncology Patient outcomes Patient Selection Patients Pediatrics Predictive Value of Tests Prognosis Random Allocation Randomized Controlled Trials as Topic Survival Rate Vidarabine - analogs & derivatives Vidarabine - pharmacology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!